Orexo partners with Lyfebulb to study addiction during pandemicWith drinking and drug use said to be spiking during the pandemic, Orexo has teamed up with US Share XOrexo partners with Lyfebulb to study addiction during pandemichttps://pharmaphorum.com/news/orexo-partners-with-lyfebulb-to-study-addiction-during-pandemic/
Orexo buys US rights to GAIA’s deprexis digital therapeuticSweden’s Orexo has announced it has bought the exclusive US rights to GAIA’s deprexis, a digital therapy to Share XOrexo buys US rights to GAIA’s deprexis digital therapeutichttps://pharmaphorum.com/news/orexo-buys-us-rights-to-gaias-deprexis-digital-therapeutic/
Orexo eyes launch of digital therapy for heavy drinkers this yearOrexo has submitted its Vorvida digital therapy for the treatment of heavy drinking for approval by the FDA, Share XOrexo eyes launch of digital therapy for heavy drinkers this yearhttps://pharmaphorum.com/news/orexo-eyes-launch-of-digital-therapy-for-heavy-drinkers-this-year/
Addiction firm Orexo licenses app for alcohol use disorderSwedish drugmaker Orexo, best known for its opioid addiction therapies, has licensed rights to a digital therapy that Share XAddiction firm Orexo licenses app for alcohol use disorderhttps://pharmaphorum.com/news/addiction-firm-orexo-licenses-app-for-alcohol-use-disorder/
Orexo partners with Gaia on digital opioid abuse therapeuticSweden’s Orexo has teamed up with Gaia Healthcare to develop a digital therapeutic to improve the effectiveness of Share XOrexo partners with Gaia on digital opioid abuse therapeutichttps://pharmaphorum.com/news/orexo-partners-with-gaia-on-digital-opioid-abuse-therapeutic/
